Detalles de la búsqueda
1.
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo.
J Med Econ
; 27(1): 473-481, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38385621
2.
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.
J Med Econ
; 27(1): 543-553, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38470512
Resultados
1 -
2
de 2
1
Próxima >
>>